• JAMA Oncology Author Interviews

  • 著者： JAMA Network
  • ポッドキャスト

JAMA Oncology Author Interviews

著者： JAMA Network
無料で聴く

  • サマリー

  • Interviews with authors of articles from JAMA Oncology. JAMA Oncology is the definitive journal for scientists, clinicians, and trainees in the field of oncology worldwide. Our original, innovative, and timely scientific and educational content provides a deeper understanding of cancer pathogenesis and recent treatment advances for our readers. JAMA Oncology aims to effectively convey the findings of important clinical research, major scientific breakthroughs, actionable discoveries, and state-of-the-art treatment pathways to the oncology community. Our goal is that successful communication of new knowledge will ultimately translate to clinical benefit for people living with and surviving cancer.
    2024 American Medical Association. All rights reserved, including those for text and data mining, AI training, and similar technologies.
    続きを読む 一部表示

あらすじ・解説

Interviews with authors of articles from JAMA Oncology. JAMA Oncology is the definitive journal for scientists, clinicians, and trainees in the field of oncology worldwide. Our original, innovative, and timely scientific and educational content provides a deeper understanding of cancer pathogenesis and recent treatment advances for our readers. JAMA Oncology aims to effectively convey the findings of important clinical research, major scientific breakthroughs, actionable discoveries, and state-of-the-art treatment pathways to the oncology community. Our goal is that successful communication of new knowledge will ultimately translate to clinical benefit for people living with and surviving cancer.
2024 American Medical Association. All rights reserved, including those for text and data mining, AI training, and similar technologies.
科学 衛生・健康的な生活 身体的病い・疾患
続きを読む 一部表示
エピソード
  • Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib

    Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib
    2024/11/21

    Interview with Hagop Kantarjian, MD, author of Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial. Hosted by Vivek Subbiah, MD.

    Related Content:

    • Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib
    続きを読む 一部表示
    19 分
  • Anti–PD-L1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma

    Anti–PD-L1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma
    2024/10/24

    Interview with Maria E. Cabanillas, MD, author of Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial. Hosted by Vivek Subbiah, MD.

    Related Content:

    • Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma
    続きを読む 一部表示
    21 分
  • Lynch Syndrome and Somatic Mismatch Repair Variants in Pancreas Cancer

    Lynch Syndrome and Somatic Mismatch Repair Variants in Pancreas Cancer
    2024/09/05

    Interview with Eileen M. O’Reilly, MD, author of Lynch Syndrome and Somatic Mismatch Repair Variants in Pancreas Cancer. Hosted by Vivek Subbiah, MD.

    Related Content:

    • Lynch Syndrome and Somatic Mismatch Repair Variants in Pancreas Cancer
    続きを読む 一部表示
    17 分

JAMA Oncology Author Interviewsに寄せられたリスナーの声

カスタマーレビュー：以下のタブを選択することで、他のサイトのレビューをご覧になれます。

Audible.co.jp

Amazon.co.jp
レビューはまだありません。